-
2023-506467-34-00
5
2020-10-20
Relapsing Multiple Sclerosis (MS)
-
2023-507816-11-00
5
2020-08-17
Macular edema due to central retinal vein occlusion
-
2022-502841-91-00
5
2020-08-12
Crohn’s Disease
-
2023-507062-34-00
7
2020-08-07
High-Risk large B-Cell lymphoma
-
2023-509242-35-00
5
2020-07-23
HR+/HER2- early breast cancer
-
2024-513276-17-00
3
2020-07-01
Acute Myeloid Leukemia
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-506588-32-00
5
2020-06-12
Relapsed and Lenalidomide-Refractory Multiple Myeloma
-
2023-509394-23-00
5
2020-06-12
Stage II melanoma arising from a primary cutaneous site after surgery
-
2024-516271-32-00
5
2020-06-03
Adenocarcinoma of the gastroesophageal junction (AEG type I-III)
-
2024-514079-17-00
10
2020-05-28
Endogenous Cushing Syndrome
-
2023-508214-42-00
5
2020-05-25
Previously treated locally advanced and unresectable or metastatic
non
-
2024-513947-94-00
4
2020-03-30
locally advanced (stage III) and not suitable for curative treatment,
-
2024-511577-29-01
5
2020-03-13
intermediate and high-risk rectal cancer
-
2024-513904-33-00
5
2020-03-11
Cerebral Adrenoleukodystrophy (CALD)
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2022-501012-34-00
5
2020-02-27
Pulmonary Arterial Hypertension
-
2023-508314-42-00
4
2020-02-27
Advanced stage intrahepatic biliary tract cancer (BTC)
-
2024-514197-50-00
9
2020-01-17
CD123 positive Acute Myeloid Leukemia
-
2024-512525-83-00
5
2020-01-07
Hypertension
-
2024-513914-36-00
4
2019-12-17
locally-advanced Anal Carcinoma, Anal cancer stage II and III
-
2024-510626-89-00
5
2019-11-18
Non-Alcoholic Steatohepatitis (NASH)
-
2024-515375-35-00
4
2019-08-26
Untreated patients with higher risk MDS and oligoblastic AML eligible
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)